NCT03314805

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: PhytoHealth Corporation · Industry
• Sex: Female
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.

Conditions

• Cancer-related Fatigue
• Neutropenia, Malignant

Interventions

Type	Name	Description
DRUG	Astragalus polysaccharides 500 mg	PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
DRUG	Placebo	500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
PROCEDURE	EC Chemotherapy	Epirubicin plus Cyclophosphamide every 21 days

Timeline

• Start date: 2018-03-01
• Primary completion: 2021-05-26
• Completion: 2021-08-27
• First posted: 2017-10-19
• Last updated: 2025-06-04

Locations

5 sites across 1 country: Taiwan